Navigation Links
MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors
Date:1/6/2011

ROCKVILLE, Md., Jan. 6, 2011 /PRNewswire/ --  MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical trial of MGAH22.  MGAH22 is an Fc-optimized monoclonal antibody developed by MacroGenics which has been shown, in pre-clinical studies, to reduce tumor growth significantly in a broad panel of HER2-expressing tumors.

"We are excited to have begun clinical testing of MGAH22, a next generation antibody that may have wide application in cancer treatment," stated Dr. Scott Koenig, President and CEO of MacroGenics.  "MGAH22 is the first Fc-engineered antibody therapeutic from our oncology pipeline to enter clinical development and represents a major milestone for MacroGenics.  Our pre-clinical studies suggest that MGAH22 may provide significant differentiation from the other HER2-targeted immunotherapeutics, including the ability to treat tumors with relatively low levels of HER2 expression."

This open-label, multi-dose, single-arm, multi-center Phase I, dose-escalation study is being conducted to define the toxicity profile, maximum tolerated dose, pharmacokinetics, immunogenicity, and potential antitumor activity of MGAH22 in patients with refractory HER2-positive breast cancer and patients with other carcinomas that overexpress HER2 for whom no standard therapy is available.  Additional information on the clinical trial can be found at: http://www.clinicaltrials.gov/ct2/show/NCT01148849.

Three internationally recognized investigators are participating in this trial, including: Dr. Howard A. Burris, III from the Sarah Cannon Research Institute, Dr. Giuseppe Giaccone from the National Cancer Institute and Dr. Yung-Jue Bang from Seoul National University Hospital.
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
2. MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio
3. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
4. Paulo F. Costa Joins MacroGenics Board of Directors
5. MacroGenics Appoints New Vice President of Business Development
6. MacroGenics Raises $25M in Series D-2 Financing
7. Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors
8. Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
9. Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
10. GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
11. SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... by researchers from the University of Leicester has ... unlocking the potential to create new materials using ... been published in the prestigious academic journal ... technique to examine in rich detail the structure ... containing an acetylene molecule and a single helium ...
(Date:7/25/2014)... 2014 The Conferee Networking committee is ... Conferee Networking. These two-hour sessions provide a unique networking ... resolve problems, discuss new techniques, or brainstorm new ideas ... a topic for consideration is August 31, 2014, and ... Conferee Networking committee will review the topics, and status ...
(Date:7/25/2014)... 25, 2014 At the request of ... a 60-day extension for the public comment period (Docket ... for Model Aircraft established by Congress as part of ... 60-day extension establishes the new deadline for comments as ... of Transportation/FAA notice published in the Federal Register on ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Gain ... Global Supply Chain of the biotech industry. Nominations ... Innovation Awards, brought to you by the ... organization of supply chain management professionals for the ... to stakeholders of the Biotech industry – Manufacturers, ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2FAA Grants Comment Extension at the Request of AMA 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3
... Nile Therapeutics,Inc. (OTC Bulletin Board: SPDU.OB), announced ... present at the Biotechnology Industry,Organization (BIO) Investor Forum ... Time at The Palace Hotel in San Francisco, ... and an update on its clinical,development programs, including ...
... Oct. 2 /PRNewswire/ - Respironics, Inc. (Nasdaq:,RESP) today ... outstanding shares,of Apollo Light Systems, Inc., a 20-year-old, ... therapy systems for melatonin suppression and,circadian rhythm sleep ... is located in American Fork, Utah and has ...
... 2 Monitorforhire.com, the,fastest source for hiring ... faster. The company has added a mobile ... immediately to work requests via,PDA or cell ... Freedman, president of monitorforhire.com says that adding ...
Cached Biology Technology:Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum 2Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum 3Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market 2Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market 3
(Date:7/27/2014)... and fungi can evade treatment by acquiring mutations in ... permanent mutations were once thought to be the only ... study has shown that microorganisms can use a temporary ... to gain the benefits of drug resistance without the ... a fungus called Mucor circinelloides, it is likely to ...
(Date:7/27/2014)... In an age of "big data," a single computer ... tasks must instead be distributed across a cluster of ... how Facebook and Google mine your web history to ... Netflix recommend your next favorite book or movie. But ... , New technologies for monitoring brain activity are generating ...
(Date:7/25/2014)... lived on the land now called California, and many ... of plants they used for food, fuel, tools, and ... desired habitat and natural resources. , Frank Lake, an ... will lead a field trip to the ... of America,s 99th Annual Meeting, in Sacramento, Cal. this ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New tools help neuroscientists analyze 'big data' 2New tools help neuroscientists analyze 'big data' 3New tools help neuroscientists analyze 'big data' 4New tools help neuroscientists analyze 'big data' 5Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... as we grow older, our bones become more brittle and ... of mass is a major reason for older bones fracturing ... on slowing down this loss. However, new research from scientists ... Laboratory (Berkeley Lab) shows that at microscopic dimensions, the age-related ...
... Winston-Salem, N.C. -- New research from Wake Forest ... electronics by developing, for the first time, an ... electrical properties, and inexpensive to produce. ... of physics at Wake Forest, her graduate students ...
... 2011 Neurotechnology , a provider ... the availability of SentiSight 3.0 , a Software ... version adds shape-based recognition and offers enhanced local-feature-based recognition ... also includes enhanced tracking of fast moving objects and ...
Cached Biology News:The brittleness of aging bones -- more than a loss of bone mass 2The brittleness of aging bones -- more than a loss of bone mass 3Flexible electronics hold promise for consumer applications 2SentiSight 3.0 Universal Object Recognition Technology Available Now From Neurotechnology 2SentiSight 3.0 Universal Object Recognition Technology Available Now From Neurotechnology 3SentiSight 3.0 Universal Object Recognition Technology Available Now From Neurotechnology 4
... AviTag E. coli Biotinylation Kit, Plasmid is designed ... E. coli expression kits. (Cat. No. 3 186 ... kit provides vectors for the easy introduction of ... expressed protein can be enzymatically mono-biotinylated by E. ...
... The ubiquitin-proteasome pathway is the major ... eukaryotic cells, where it catalyzes the ... and the rapid elimination of proteins ... 1998; Hochstrasser 1996). The critical protease ...
... technology enables sensitive, fast and specific detection ... Short hybridisation time ( ... chromosome spreads Multiplex capability Available ... Probes available with different labels. ...
... * Source rat ... T25 plated cells $550.00, * ... 120 population doublings, * This ... complete ,growth medium M55007-08 and ...
Biology Products: